NRX Pharmaceuticals Analyst Price Targets - Benzinga

NRX Pharmaceuticals Inc

NRXPNASDAQ

Trade with Public

Trade with Public

$3.45

-0.11-3.09%

al cierre: Aug 21, 5:00 PM EST

$3.51

-0.05-1.4%

Premercado: 4:02 AM EST

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

NRX Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for NRX Pharmaceuticals (NRXP).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$29Upside to Avg. PT+738.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 18, 2026	BTIG	Thomas Shrader	Maintained	Buy	$10
Aug 7, 2026	BTIG	Thomas Shrader	PT Cut	Buy	$25→$10
May 5, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Apr 27, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$45
Apr 27, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$48→$49
Apr 23, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Apr 20, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 24, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 24, 2026	BTIG	Thomas Shrader	Maintained	Buy	$25
Mar 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 16, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 9, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 3, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$40→$45
Feb 18, 2026	BTIG	Thomas Shrader	Maintained	Buy	$25
Feb 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Jan 15, 2026	BTIG	Thomas Shrader	Maintained	Buy	$25
Jan 5, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Jan 2, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$47→$48
Dec 16, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$40
Dec 3, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10

BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target from $25 to $10.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $49

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $48 to $49.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $45

HC Wainwright & Co. analyst Patrick R. Trucchio maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $40 to $45.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.

Benzinga Newsdesk